Skip to Content

Join the 'Atracurium' group to help and get support from people like you.

Atracurium News

Forward-Thinking Tips for Back Pain

Posted 19 Jan 2017 by Drugs.com

WEDNESDAY, Jan. 18, 2017 – Back pain is common but not inevitable, an orthopedist says. Roughly eight out of 10 people will suffer significant back pain at least once in their lifetime – but there are ways to reduce the risk, said Dr. Mark Knaub of Penn State Hershey Medical Center. Muscle, ligament or tendon strains (soft tissue injuries) are the most common causes of back pain. These injuries can occur from falls or activities involving lifting, twisting or bending, said Knaub, chief of the medical center's adult orthopedic spine service. When pain strikes, you can ease it with anti-inflammatory drugs and muscle relaxants. And physical therapy can reduce the risk of back pain becoming chronic, he suggested. "Physical therapy can give you techniques to lessen your symptoms in the short term, and get you back to being active and mobile," Knaub said in a Penn State news release. "In ... Read more

Related support groups: Pain, Back Pain, Muscle Pain, Ibuprofen, Naproxen, Soma, Meloxicam, Flexeril, Advil, Baclofen, Cyclobenzaprine, Diclofenac, Voltaren, Aleve, Mobic, Methocarbamol, Zanaflex, Botox, Motrin, Tizanidine

FDA Medwatch Alert: Atracurium Besylate Injection by Sagent Pharmaceuticals: Recall - Potential Impact on Product Sterility

Posted 24 Feb 2015 by Drugs.com

ISSUE: Sagent Pharmaceuticals, Inc. announced the voluntary nationwide recall of two lots of Atracurium Besylate Injection, USP, 50mg/5mL single-dose vials (NDC 25021-659-05) and four lots of Atracurium Besylate Injection, USP, 100mg/10mL multi-dose vials (NDC 25021-672-10) manufactured by Emcure Pharmaceuticals Ltd. and distributed by Sagent. Sagent has initiated this voluntary recall of Atracurium Besylate Injection, USP, 50mg/5mL and 100mg/10mL to the user level due to FDA observations pertaining to aseptic and GMP practices at the manufacturer’s site potentially impacting product sterility. Non-sterility of a drug administered via the intravenous route has the potential to result in infections, which could be fatal, especially in patients who are immunocompromised. BACKGROUND: The lot numbers being recalled are VATA012, VATA015 (50mg/5mL) and VATB012, VATB013, VATB014, VATB017 ( ... Read more

Related support groups: Atracurium, Tracrium, Anesthetic Adjunct

Ask a Question

Further Information

Related Condition Support Groups

Anesthetic Adjunct

Related Drug Support Groups

Tracrium

Atracurium Patient Information at Drugs.com